Senolyticsreview2021

Cellular senescence in ageing: from mechanisms to therapeutic opportunities.

Nature reviews. Molecular cell biology

confidence

Key findings

Review of cellular senescence mechanisms and therapeutic opportunities (senolytic/senomorphic therapies); no reported clinical or biological endpoints.

View source on PubMed (PMID 33328614) ↗

Population
Review article (no clinical population)
Blinding
not_reported
Controls
not_reported
Drug class
senolytic class
Full abstract

Cellular senescence, first described in vitro in 1961, has become a focus for biotech companies that target it to ameliorate a variety of human conditions. Eminently characterized by a permanent proliferation arrest, cellular senescence occurs in response to endogenous and exogenous stresses, including telomere dysfunction, oncogene activation and persistent DNA damage. Cellular senescence can also be a controlled programme occurring in diverse biological processes, including embryonic development. Senescent cell extrinsic activities, broadly related to the activation of a senescence-associated secretory phenotype, amplify the impact of cell-intrinsic proliferative arrest and contribute to impaired tissue regeneration, chronic age-associated diseases and organismal ageing. This Review discusses the mechanisms and modulators of cellular senescence establishment and induction of a senescence-associated secretory phenotype, and provides an overview of cellular senescence as an emerging opportunity to intervene through senolytic and senomorphic therapies in ageing and ageing-associated diseases.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.